drug development – Buonaiuto@Work

Moderator at the ITDACH Roundtable meeting on Artificial Intelligence and IoT on April 25th, 2024

Massimo2024-03-010699 views

I’ll be moderating the upcoming roundtable on Artificial Intelligence and IoT on April 25th, 2024. We’ll be delving into some fascinating topics, including Generative AI in the Enterprise, enhancing creativity and content generation, Natural Language generation (NLG) for business communication, and AI-driven product and service Innovation. We’ll also be exploring the importance of personalization and customer experience, and how to make the most of new technology in corporate organizations.

Speaker at the Global TechOps Leadership Team of Incyte on Generative AI – 20th February 2024 in Morges, Switzerland

Massimo2023-12-120657 views

Incite’s event highlights the pioneering integration of Generative AI in the pharmaceutical sector. The focus will be on AI’s transformative impact on workforce, drug development, supply chain management, manufacturing, quality assurance, and regulatory compliance.

The critical role of HL7 and FHIR in Pharmaceutical Innovation: A Case Study Approach

Massimo2023-04-060285 views

Highlighting the transformative role of Health Level Seven International (HL7) and Fast Healthcare Interoperability Resources (FHIR) in the pharmaceutical industry, emphasizing their importance in enhancing drug development, patient outcomes, and regulatory compliance. HL7 and FHIR facilitate seamless data exchange across healthcare systems, enabling pharmaceutical companies to leverage comprehensive patient data for accelerated drug development and improved therapeutic strategies. The integration of FHIR in a global R&D company is showcased as a case study, illustrating significant improvements in clinical trial efficiency, data security, and regulatory compliance. The implementation process involved strategic planning, infrastructure upgrades, software development, and rigorous data validation to ensure compliance with FHIR standards. This case study underscores the critical role of data standardization and advanced analytics in pharmaceutical innovation, highlighting the benefits of real-time data access, efficient patient recruitment, remote monitoring, and streamlined regulatory processes.